CBX7 and central nervous system cancer: Further, bisulphite sequencing confirmed the hypermethylation of Cbx7 promoter in GBM samples (20.71%), glioma derived cell lines (39.60%) as compared to control brain samples (5.75%) (Fig. 1H).